Molecular profiling of melanoma and the evolution of patient-specific therapy

Seminars in Oncology

Volumn 38, Issue 2, 2011, Pages 236-242

  Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLTRYPTOPHAN; ALBINTERFERON ALPHA2B; B RAF KINASE; CARBOPLATIN; DACARBAZINE; DACLIZUMAB; DENILEUKIN DIFTITOX; GAMMA SECRETASE INHIBITOR; IMATINIB; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 2; IPILIMUMAB; LAPATINIB; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MONOCLONAL ANTIBODY; NILOTINIB; PACLITAXEL; PD 1 MONOCLONAL ANTIBODY; PLX 4032; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SORAFENIB; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR; TEMOZOLOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

CANCER VACCINES; GENE EXPRESSION PROFILING; HUMANS; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 79952980159     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.01.004     Document Type: Article

References (65)

1. J.M. Richards, T.A. Gilewski, K. Ramming, B. Mitchel, L.L. Doane, and N.J. Vogelzang Effective chemotherapy for melanoma after treatment with interleukin-2 Cancer 69 1992 427 429
2. M.B. Atkins, J. Hsu, and S. Lee Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 26 2008 5748 5754
3. J.A. Curtin, J. Fridlyand, and T. Kageshita Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147 (Pubitemid 41653105)
4. P.G. Coulie, V. Karanikas, and D. Colau A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 Proc Natl Acad Sci U S A 21 2001 21
5. S.A. Rosenberg, R.M. Sherry, and K.E. Morton Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma J Immunol 175 2005 6169 6176 (Pubitemid 41508105)
6. T.F. Gajewski, Y. Meng, and H. Harlin Chemokines expressed in melanoma metastases associated with T cell infiltration J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 25 18S 2007 8501
7. T.F. Gajewski, J. Louahed, and V.G. Brichard Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy Cancer J 16 2010 399 403
8. H. Harlin, Y. Meng, and A.C. Peterson Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment Cancer Res 69 2009 3077 3085
9. T.F. Gajewski, Y. Zha, B. Thurner, and G. Schuler Association of gene expression profile in melanoma and survival to a dendritic cell-based vaccine J Clin Oncol 27 15s 2009 9002
10. J.F. Vansteenkiste, M. Zielinski, and I.J. Dahabreh Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC) J Clin Oncol 26 20 suppl 2008 abstract 7501
11. H. Harlin, T.V. Kuna, A.C. Peterson, Y. Meng, and T.F. Gajewski Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites Cancer Immunol Immunother 55 2006 1185 1197 (Pubitemid 43992045)
12. A. Zippelius, P. Batard, and V. Rubio-Godoy Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance Cancer Res 64 2004 2865 2873 (Pubitemid 38500627)
13. V. Appay, C. Jandus, and V. Voelter New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site J Immunol 177 2006 1670 1678 (Pubitemid 44092503)
14. R. Mortarini, A. Piris, and A. Maurichi Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma Cancer Res 63 2003 2535 2545 (Pubitemid 36605194)
15. T.F. Gajewski Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment Clin Cancer Res 13 2007 5256 5261 (Pubitemid 47510348)
16. D.H. Munn, M. Zhou, and J.T. Attwood Prevention of allogeneic fetal rejection by tryptophan catabolism Science 281 1998 1191 1193 (Pubitemid 28406294)
17. H. Dong, and L. Chen B7-H1 pathway and its role in the evasion of tumor immunity J Mol Med 81 2003 281 287 (Pubitemid 36718324)
18. T. Nomura, and S. Sakaguchi Naturally arising CD25+CD4+ regulatory T cells in tumor immunity Curr Top Microbiol Immunol 293 2005 287 302 (Pubitemid 40791234)
19. R.H. Schwartz T cell anergy Annu Rev Immunol 21 2003 305 334 (Pubitemid 37174534)
20. V.G. Brichard, and D. Lejeune Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease Expert Opin Biol Ther 8 2008 951 968 (Pubitemid 352007006)
21. A.J. Muller, W.P. Malachowski, and G.C. Prendergast Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors Expert Opin Ther Targets 9 2005 831 849 (Pubitemid 41131682)
22. C. Uyttenhove, L. Pilotte, and I. Theate Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat Med 9 2003 1269 1274 (Pubitemid 37279849)
23. C. Blank, I. Brown, and A.C. Peterson PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells Cancer Res 64 2004 1140 1145 (Pubitemid 38176921)
24. L. Zhang, T.F. Gajewski, and J. Kline PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model Blood 114 2009 1545 1552
25. R.P. Sutmuller, L.M. van Duivenvoorde, and A. van Elsas Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses J Exp Med 194 2001 823 832 (Pubitemid 32983017)
26. I.E. Brown, C. Blank, J. Kline, A.K. Kacha, and T.F. Gajewski Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection J Immunol 177 2006 4521 4529 (Pubitemid 44469783)
27. X. Liu, N. Shin, and H.K. Koblish Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Blood 115 2010 3520 3530
28. M. Sznol, J.D. Powderly, and D.C. Smith Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies J Clin Oncol 28 15s 2010 abstract 2506
29. J. Dannull, Z. Su, and D. Rizzieri Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J Clin Invest 115 2005 3623 3633 (Pubitemid 43121851)
30. A.J. Rech, and R.H. Vonderheide Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells Ann N Y Acad Sci 1174 2009 99 106
31. M.A. Rasku, A.L. Clem, and S. Telang Transient T cell depletion causes regression of melanoma metastases J Transl Med 6 2008 12
32. S.A. Rosenberg, and M.E. Dudley Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes Proc Natl Acad Sci U S A 101 Suppl 2 2004 14639 14645 (Pubitemid 39346736)
33. R.J. Sullivan, Y. Hoshida, and J. Brunet A single center experience with high-dose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response J Clin Oncol 27 15s 2009 abstract 9003
34. O. Hamid, S.D. Chasalow, Z. Tsuchihashi, S. Alaparthy, S. Galbraith, and D. Berman Association of baseline and on-study tumor biopsy markers with clinical activity in patients with advanced melanoma treated with ipilimumab J Clin Oncol 27 15s 2009 abstract 9008
35. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 2002 949 954 (Pubitemid 34716871)
36. T. Eisen, T. Ahmad, and K.T. Flaherty Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Br J Cancer 95 2006 581 586 (Pubitemid 44325897)
37. K.T. Flaherty, J. Schiller, and L.M. Schuchter A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel Clin Cancer Res 14 2008 4836 4842
38. K.T. Flaherty, S.J. Lee, and L.M. Schuchter Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma J Clin Oncol 28 15s 2010 abstract 8511
39. T.F. Gajewski, D. Niedzwiecki, and J. Johnson Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104 J Clin Oncol 24 18s 2006 abstract 8014
40. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
41. C. Beadling, E. Jacobson-Dunlop, and F.S. Hodi KIT gene mutations and copy number in melanoma subtypes Clin Cancer Res 14 2008 6821 6828
42. I. Satzger, T. Schaefer, and U. Kuettler Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas Br J Cancer 99 2008 2065 2069
43. M.C. Heinrich, C.L. Corless, and G.D. Demetri Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 2003 4342 4349 (Pubitemid 46621810)
44. F.S. Hodi, P. Friedlander, and C.L. Corless Major response to imatinib mesylate in KIT-mutated melanoma J Clin Oncol 26 2008 2046 2051
45. J. Lutzky, J. Bauer, and B.C. Bastian Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation Pigment Cell Melanoma Res 21 2008 492 493 (Pubitemid 351990966)
46. A. Quintas-Cardama, A.J. Lazar, S.E. Woodman, K. Kim, M. Ross, and P. Hwu Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib Nat Clin Pract Oncol 5 2008 737 740
47. I. Satzger, U. Kuttler, B. Volker, F. Schenck, A. Kapp, and R. Gutzmer Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapycase report and review of the literature Dermatology 220 2010 77 81
48. K. Wyman, M.B. Atkins, and V. Prieto Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy Cancer 106 2006 2005 2011 (Pubitemid 43673217)
49. K.B. Kim, O. Eton, and D.W. Davis Phase II trial of imatinib mesylate in patients with metastatic melanoma Br J Cancer 99 2008 734 740
50. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003 (Pubitemid 40349502)
51. H.A. Tawbi, S. Buch, and P. Pancoska Prediction of response to alkylator-based chemotherapy in metastatic melanoma (MM) using gene expression and promoter methylation signatures J Clin Oncol 27 15s 2010 abstract 9009
52. T.F. Gajewski, J. Sosman, and S.L. Gerson Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma Clin Cancer Res 11 2005 7861 7865 (Pubitemid 41611631)
53. D. Massi, F. Tarantini, and A. Franchi Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma Mod Pathol 19 2006 246 254 (Pubitemid 43117609)
54. A.W. Tolcher, S.M. Mikulski, and W.A. Messersmith A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors J Clin Oncol 28 15s 2010 abstract 2502
55. J.A. Curtin, M.S. Stark, D. Pinkel, N.K. Hayward, and B.C. Bastian PI3-kinase subunits are infrequent somatic targets in melanoma J Invest Dermatol 126 2006 1660 1663
56. X.P. Zhou, O. Gimm, H. Hampel, T. Niemann, M.J. Walker, and C. Eng Epigenetic PTEN silencing in malignant melanomas without PTEN mutation Am J Pathol 157 2000 1123 1128
57. J.T. Celebi, I. Shendrik, D.N. Silvers, and M. Peacocke Identification of PTEN mutations in metastatic melanoma specimens J Med Genet 37 2000 653 657
58. T.D. Prickett, N.S. Agrawal, and X. Wei Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 Nat Genet 41 2009 1127 1132
59. D. Bilancia, G. Rosati, A. Dinota, D. Germano, R. Romano, and L. Manzione Lapatinib in breast cancer Ann Oncol 18 Suppl 6 2007 vi26 vi30
60. N. Puri, S. Ahmed, and V. Janamanchi c-Met is a potentially new therapeutic target for treatment of human melanoma Clin Cancer Res 13 2007 2246 2253 (Pubitemid 46649894)
61. L. Larue, and V. Delmas The WNT/Beta-catenin pathway in melanoma Front Biosci 11 2006 733 742 (Pubitemid 43258176)
62. J.L. Messina, H. Yu, A.I. Riker, P.N. Munster, R.L. Jove, and A.I. Daud Activated stat-3 in melanoma Cancer Control 15 2008 196 201
63. L. Burdelya, M. Kujawski, and G. Niu Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects J Immunol 174 2005 3925 3931 (Pubitemid 40395966)
64. Smalley KS, Sondak VK. Melanomaan unlikely poster child for personalized cancer therapy. N Engl J Med;363:876-8.
65. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol;7:340-7.